ADAMTS13 and fatty liver disease: Although our study was one of the few to prove the intimate link between low ADAMTS13 activity in obese patients or patients with fatty liver and unmet treatment outcomes in COVID-19, it is still limited by the retrospective nature of the study, the relatively small number of patients with extreme obesity grades, and fluctuations in ADAMTS13 activity during the hospitalization course.